RxDoctor Payments Data

Matthew Lilly, MD

Psychiatry · Morgan Hill, CANPI 1346571643

Payments from drug & device makers

$3,482in general payments, 2019–2025

Across 120 payments — averaging $29.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$933
  • Alkermes, Inc.$621
  • Johnson & Johnson$480
  • Neurocrine Biosciences, Inc.$415
  • Otsuka America Pharmaceutical, Inc.$376
  • Indivior Inc.$237
  • plus $420 from 8 others

What the payments were for

  • Food & beverage$3,15791%
  • Education$3249%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,482 in reported general payments places this provider in the 85th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$32,069
Medicare patients
39
Services billed
186

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate148$537,753
Invega TrinzaPaliperidone Palmitate14$156,612
AustedoDeutetrabenazine14$140,778
AristadaAripiprazole Lauroxil33$108,062
Clozapine OdtClozapine158$102,244
Austedo XrDeutetrabenazine16$85,817
LybalviOlanzapine/Samidorphan Malate46$65,086
Clozapine570$61,524
OzempicSemaglutide57$58,810
UzedyRisperidone15$51,274
FanaptIloperidone14$45,013
RexultiBrexpiprazole30$43,546
Olanzapine624$41,035
Paliperidone ErPaliperidone144$32,713
CaplytaLumateperone Tosylate17$25,300

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$480$694,366162 claims
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr, Uzedy$933$277,86945 claims
Alkermes, Inc.Aristada, Lybalvi$621$173,14779 claims
Otsuka America Pharmaceutical, Inc.Rexulti$376$43,54630 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$20$25,30017 claims
AbbVieLinzess$18$12,48121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Morgan Hill

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →